DYN
Dyne Therapeutics Inc

2,617
Mkt Cap
$2.94B
Volume
2.03M
52W High
$31.32
52W Low
$6.36
PE Ratio
-5.63
DYN Fundamentals
Price
$20.12
Prev Close
$20.60
Open
$21.05
50D MA
$16.62
Beta
1.79
Avg. Volume
2.81M
EPS (Annual)
-$3.37
P/B
4.25
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eighteen research firms that are presently covering the stock...
MarketBeat·17h ago
News Placeholder
More News
News Placeholder
Dyne Therapeutics (NASDAQ:DYN) Trading 9% Higher - Here's What Happened
Dyne Therapeutics (NASDAQ:DYN) Shares Up 9% - Still a Buy...
MarketBeat·2d ago
News Placeholder
Candriam S.C.A. Purchases 60,793 Shares of Dyne Therapeutics, Inc. $DYN
Candriam S.C.A. grew its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 13.1% during the second quarter, according to the company in its most recent filing with the...
MarketBeat·4d ago
News Placeholder
Dyne Therapeutics (NASDAQ:DYN) Price Target Cut to $17.00 by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. lowered their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday...
MarketBeat·4d ago
News Placeholder
Oppenheimer Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $11.00
Oppenheimer reduced their price objective on Dyne Therapeutics from $13.00 to $11.00 and set a "market perform" rating for the company in a research report on Wednesday...
MarketBeat·7d ago
News Placeholder
HC Wainwright Predicts Lower Earnings for Dyne Therapeutics
Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Investment analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for shares of Dyne Therapeutics in a research report...
MarketBeat·11d ago
News Placeholder
Lifesci Capital Has Positive Outlook of DYN FY2025 Earnings
Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Analysts at Lifesci Capital boosted their FY2025 earnings estimates for Dyne Therapeutics in a research note issued to investors on Thursday...
MarketBeat·11d ago
News Placeholder
Dyne Therapeutics (NASDAQ:DYN) Given New $30.00 Price Target at Royal Bank Of Canada
Royal Bank Of Canada increased their price target on Dyne Therapeutics from $23.00 to $30.00 and gave the company an "outperform" rating in a report on Thursday...
MarketBeat·13d ago
News Placeholder
Dyne Therapeutics (NASDAQ:DYN) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of...
MarketBeat·14d ago
News Placeholder
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis
Stocktwits·24d ago

Latest DYN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.